title: Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome.
abstract: In women with polycystic ovary syndrome, chromium picolinate (200 microg/d) improves glucose tolerance compared with placebo but does not improve ovulatory frequency or hormonal parameters. This pilot study indicates that future studies in the polycystic ovary syndrome population should examine higher dosages or longer durations of treatment.
authors.affiliation: Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, Texas 78229, USA. scott.lucidi@us.army.mil
authors.forename: R Scott
authors.initials: RS
authors.lastname: Lucidi
authors.forename: Angela C
authors.initials: AC
authors.lastname: Thyer
authors.forename: Carol A
authors.initials: CA
authors.lastname: Easton
authors.forename: Alan E C
authors.initials: AE
authors.lastname: Holden
authors.forename: Robert S
authors.initials: RS
authors.lastname: Schenken
authors.forename: Robert G
authors.initials: RG
authors.lastname: Brzyski
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D018149:Glucose Intolerance / Q000188:drug therapy; D006801:Humans; D007333:Insulin Resistance; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008597:Menstrual Cycle / Q000187:drug effects*; D010053:Ovary / Q000502:physiology; D010060:Ovulation / Q000187:drug effects; D010848:Picolinic Acids / Q000008:administration & dosage*; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D007502:Iron Chelating Agents; D010848:Picolinic Acids; C030614:picolinic acid